167 related articles for article (PubMed ID: 22508307)
1. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
Haaland RE; Evans-Strickfaden T; Holder A; Pau CP; McNicholl JM; Chaikummao S; Chonwattana W; Hart CE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3592-6. PubMed ID: 22508307
[TBL] [Abstract][Full Text] [Related]
2. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
Bunge K; Macio I; Meyn L; Noguchi L; Parniak MA; Schwartz JL; Moncla B; Hillier S
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):337-43. PubMed ID: 22495787
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.
Ventuneac A; Carballo-Diéguez A; McGowan I; Dennis R; Adler A; Khanukhova E; Price C; Saunders T; Siboliban C; Anton P
AIDS Behav; 2010 Jun; 14(3):618-28. PubMed ID: 19757017
[TBL] [Abstract][Full Text] [Related]
4. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
Patton DL; Sweeney YT; Balkus JE; Rohan LC; Moncla BJ; Parniak MA; Hillier SL
Antimicrob Agents Chemother; 2007 May; 51(5):1608-15. PubMed ID: 17353240
[TBL] [Abstract][Full Text] [Related]
5. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
Schwartz JL; Kovalevsky G; Lai JJ; Ballagh SA; McCormick T; Douville K; Mauck CK; Callahan MM
Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
[TBL] [Abstract][Full Text] [Related]
6. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
7. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.
Anton PA; Saunders T; Elliott J; Khanukhova E; Dennis R; Adler A; Cortina G; Tanner K; Boscardin J; Cumberland WG; Zhou Y; Ventuneac A; Carballo-Diéguez A; Rabe L; McCormick T; Gabelnick H; Mauck C; McGowan I
PLoS One; 2011; 6(9):e23243. PubMed ID: 21969851
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.
Yang H; Parniak MA; Isaacs CE; Hillier SL; Rohan LC
AAPS J; 2008 Dec; 10(4):606-13. PubMed ID: 19089644
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
Richardson-Harman N; Mauck C; McGowan I; Anton P
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1422-33. PubMed ID: 22900504
[TBL] [Abstract][Full Text] [Related]
10. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
Hossain MM; Parniak MA
J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
[TBL] [Abstract][Full Text] [Related]
11. Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques.
McConville C; Smith JM; McCoy CF; Srinivasan P; Mitchell J; Holder A; Otten RA; Butera S; Doncel GF; Friend DR; Malcolm RK
Drug Deliv Transl Res; 2015 Feb; 5(1):27-37. PubMed ID: 25787337
[TBL] [Abstract][Full Text] [Related]
12. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.
Keller MJ; Carpenter CA; Lo Y; Einstein MH; Liu C; Fredricks DN; Herold BC
PLoS One; 2012; 7(10):e46901. PubMed ID: 23056520
[TBL] [Abstract][Full Text] [Related]
13. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits.
Aranha CC; Gupta SM; Reddy KV
Cytokine; 2008 Jul; 43(1):63-70. PubMed ID: 18513989
[TBL] [Abstract][Full Text] [Related]
15. A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781.
Clark MR; Johnson TJ; McCabe RT; Clark JT; Tuitupou A; Elgendy H; Friend DR; Kiser PF
J Pharm Sci; 2012 Feb; 101(2):576-87. PubMed ID: 21976110
[TBL] [Abstract][Full Text] [Related]
16. Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781.
McConville C; Friend D
Eur J Pharm Biopharm; 2013 Apr; 83(3):322-9. PubMed ID: 23159711
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Keller MJ; Madan RP; Torres NM; Fazzari MJ; Cho S; Kalyoussef S; Shust G; Mesquita PM; Louissaint N; Chen J; Cohen HW; Diament EC; Lee AC; Soto-Torres L; Hendrix CW; Herold BC
PLoS One; 2011 Jan; 6(1):e16475. PubMed ID: 21283552
[TBL] [Abstract][Full Text] [Related]
18. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.
Grammen C; Ariën KK; Venkatraj M; Joossens J; Van der Veken P; Heeres J; Lewi PJ; Haenen S; Augustyns K; Vanham G; Augustijns P; Brouwers J
Antiviral Res; 2014 Jan; 101():113-21. PubMed ID: 24269474
[TBL] [Abstract][Full Text] [Related]
19. Assessing the potential of the Woman's Condom for vaginal drug delivery.
Kramzer LF; Cohen J; Schubert J; Dezzutti CS; Moncla BJ; Friend D; Rohan LC
Contraception; 2015 Sep; 92(3):254-60. PubMed ID: 25998936
[TBL] [Abstract][Full Text] [Related]
20. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Cost M; Dezzutti CS; Clark MR; Friend DR; Akil A; Rohan LC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3058-66. PubMed ID: 22430977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]